Meningitis Diagnosis and Treatment Market Overview:

The global meningitis diagnosis and treatment market can reach a size of USD 430.20 million by 2023, as per the latest report of Market Research Future (MRFR). It is likely to register a CAGR of 3.38% from 2018 to 2023 (forecast period) due to rising prevalence of viral, bacterial, and fungal infections. According to the National Center for Biotechnology Information (NCBI), nearly 8.7 million cases of meningitis were reported in 2015. The large patient pool susceptible to meningitis can offer numerous growth opportunities to the market.

Rising prevalence of meningitis has created the need for point of care diagnostic centers. According to the National Health Council, increasing number of Americans likely to be affected by chronic diseases and it can touch 157 million by 2020. These centers can detect the disease at an early stage and provide patients with preventive care. Moreover, development of drugs for the treatment of meningitis can create opportunities for the market.

Meningitis Diagnosis and Treatment Market Segmentation Analysis:

The global meningitis diagnosis and treatment market is segmented by type, treatment & diagnosis, and end-user.

By type, viral meningitis held 43.4% share in 2017, followed by bacterial meningitis, fungal meningitis, and others. Viral meningitis is expected to register moderate growth during the assessment period. Bacterial meningitis is likely to register highest CAGR of 3.54% over the forecast period.

By treatment & diagnosis, treatment accounted for noticeable market share in 2017, with diagnosis holding second place in the same year. The treatment segment is sub-segmented into antifungal drugs, steroids, antibiotics, and others. While the diagnosis segment is divided into spinal tap (lumbar puncture), imaging techniques, blood test, and others. The treatment segment can display 3.54% CAGR over the forecast period. This can be credited to sales of meningitis treatment drugs, namely anticonvulsants, antiemetics, and antifungal drugs.

By end-user, hospitals & clinics accounted for largest market share in 2017, followed by diagnostic centers and others. Hospitals & clinics can exhibit highest CAGR over the forecast period. This can be attributed to the rising number of meningitis treatment procedures conducted in hospitals across China and India. Diagnostic centers, on the other hand, can generate by 2023.

Meningitis Diagnosis and Treatment Market Regional Analysis:

Geographically, the meningitis diagnosis and treatment market is segmented into Europe, Asia Pacific (APAC), Americas, and the Middle East & Africa (MEA). The Americas dominated the market with 37.4% share in 2017, followed by Europe, Asia-Pacific and the Middle East & Africa.

Although the Americas accounted for the largest market share, the region is predicted to display 2.92% CAGR over the forecast period. Presence of various players and rapid approval of drugs can positively impact the revenue margins of the meningitis and diagnosis treatment market. Availability of advanced techniques such as lumbar puncture in diagnostic centers is likely to bolster regional market demand.

The Asia-Pacific region is touted to exhibit Highest CAGR during the assessment period. This is due to initiatives by healthcare providers to detect neurological disorders at an early stage.

The Europe meningitis diagnosis and treatment market are driven by the slew of medical diagnostic devices in the U.K., France, and Germany. Rise in healthcare spending by these nations to lower the mortality rate caused by meningitis can work in favor of the market. Utilization of advanced imaging techniques such as computed tomography for the diagnosis of chronic diseases at an early stage is predicted to contribute to market growth.

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/meningitis-diagnosis-and-treatment-market-5730

Meningitis Diagnosis and Treatment Market Competitive Analysis:

Prominent names in the meningitis diagnosis and treatment market include B. Braun Melsungen AG (Germany), Sanofi (France), Pfizer Inc. (U.S.), Siemens Healthcare Private Limited (Germany), GlaxoSmithKline PLC (U.K.), Merck KGaA (U.S.), Baxter (U.S.), Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Luminex Corporation (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), and Cepheid (U.S.). The market is characterized by partnerships, mergers, expansions, and expansions.